Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma

Published:2019-04 Issue: Volume:42 Page:363-374
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Long Junyu^ORCID,Wang Anqiang,Bai Yi,Lin Jianzhen,Yang Xu,Wang Dongxu,Yang Xiaobo,Jiang Yan,Zhao Haitao^ORCID

Funder

International Science and Technology Cooperation

Capital Special Research Project for Health Development

the Beijing Natural Science Foundation

Fundamental Research Funds for the Central Universities

the CAMS Innovation Fund for Medical Science (CIFMS)

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference61 articles.

1. Progress in non-invasive detection of liver fibrosis;Li;Cancer Biol Med,2018

2. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N. Engl. J. Med.,2008

4. AASLD guidelines for the treatment of hepatocellular carcinoma;Heimbach;Hepatology,2018

5. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients;Huang;Digestion,2012

Cited by 242 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Identification and validation of a novel robust glioblastoma prognosis model based on bioinformatics;Heliyon;2024-09

3. Development and validation of a novel immune‒metabolic-Based classifier for hepatocellular carcinoma;Heliyon;2024-09

4. A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma;Clinical and Translational Oncology;2024-08-23

5. Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target;BMC Cancer;2024-08-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3